CatalYm Appoints Drug Development Leader Roy Baynes to its Board of Directors
MUNICH--(BUSINESS WIRE)--CatalYm announced that maturing Phase 2a results from its ongoing GDFATHER-2 trial (GDF-15 Antibody-mediaTed Human Effector Cell Relocation Phase 2) (NCT04725474) were presented today in an oral presentation at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2023 in Geneva, Switzerland. The data highlights that treatment with a combination of CatalYm’s lead candidate visugromab and nivolumab achieves compelling anti-tumoral activity in (as per strict criteria) anti-PD-1/PD-L1 relapsed/refractory non-small cell lung cancer (NSCLC) and urothelial cancer (UC) patients while retaining an excellent safety and tolerability profile. Visugromab is a monoclonal antibody designed to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15), a central mediator of immune resistance to cancer therapies. The presentation by International Coordinating Investigator Prof. Ignacio Melero, MD, PhD, Co-Director of Immunology and Immunotherapy (CIMA) at the Universidad de Navarra, Pamplona/Spain, expands the clinical data for visugromab significantly and highlights the benefits that neutralizing GDF-15 can provide for patients with metastatic solid tumors.
CatalYm’s solid tumor candidate, which targets a protein previously explored in obesity, has boosted responses in combination with an immune checkpoint inhibitor in an early-stage trial. The results pave the way for the next stage of controlled studies in earlier lines of disease.
CatalYm Presents Data at SITC 2023 Annual Meeting
CatalYm commences Dosing in a Phase 2 Study with Visugromab
MUNICH--(BUSINESS WIRE)--CatalYm today announced new preclinical data expanding the mechanistic understanding of how GDF-15 plays a key role in cancer therapy resistance. The results will be presented in a poster session at the European Society for Medical Oncology (ESMO) Congress 2023 in Madrid, Spain on Sunday, October 22nd by CatalYm’s CSO, Dr. Christine Schuberth-Wagner. The data are the first to show that GDF-15 has an inhibitory effect on the activation of M1 macrophages. These specific myeloid lineage immune cells are central to the initiation of immune responses, including the secretion of pro-inflammatory cytokines and chemokines, presentation of antigens as well as direct antitumor cytotoxicity.
CatalYm Publishes Data in Nature Communications Describing GDF-15 as a Central Factor of anti-PD-1 Resistance
MUNICH--(BUSINESS WIRE)--CatalYm today announced first Phase 2a data from its ongoing GDFather-2 trial (GDF-15 Antibody-mediaTed Human Effector Cell Relocation Phase 2) (NCT04725474) at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023 in Chicago, Illinois. The early data presented during today’s oral “Developmental Therapeutics-Immunotherapy” session revealed lasting and confirmed responses in several solid tumor types investigated following treatment with visugromab and the anti-PD-1 inhibitor nivolumab. In addition, the combination continues to demonstrate a good safety and tolerability profile across all cohorts. CatalYm’s lead candidate, visugromab, is a humanized, monoclonal antibody designed to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15), a central regulator of tumor resistance development.
MUNICH--(BUSINESS WIRE)--CatalYm today announced that the first results from its ongoing Phase 2a trial “GDFATHER-2” (GDF-15 Antibody-mediaTed Human Effector Cell Relocation Phase 2) will be featured in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023 in Chicago. The trial is evaluating CatalYm’s lead GDF-15 neutralizing antibody visugromab in combination with immune checkpoint inhibitor nivolumab in last-line, anti-PD-1/PD-L1 relapsed/refractory patients. Growth and differentiation factor 15 (GDF-15) is recognized as a negative regulator of antitumoral T cell activity preventing T cell recruitment to the tumor microenvironment as well as potently suppressing an adaptive immune response by additional mechanisms recently identified. The ASCO Annual Meeting will be held in Chicago, Illinois, from June 2 to 6, 2023.
CatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors